DOVATO Drug Patent Profile

When do Dovato patents expire, and when can generic versions of Dovato launch?

Dovato is a drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and two patent family members in forty-nine countries.

The generic ingredient in DOVATO is dolutegravir sodium; lamivudine. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Dovato

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DOVATO

International Patents:	302
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	45
Clinical Trials:	9
Patent Applications:	275
Drug Prices:	Drug price information for DOVATO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DOVATO
What excipients (inactive ingredients) are in DOVATO?	DOVATO excipients list
DailyMed Link:	DOVATO at DailyMed

See drug prices for DOVATO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DOVATO

NDA:

211994

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DOVATO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ViiV Healthcare	PHASE3
Johns Hopkins University	PHASE3
ViiV Healthcare	PHASE4

See all DOVATO clinical trials

Pharmacology for DOVATO

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	HIV Integrase Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors Organic Cation Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for DOVATO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DOVATO	Tablets	dolutegravir sodium; lamivudine	50 mg/300 mg	211994	1	2019-07-30

US Patents and Regulatory Information for DOVATO

DOVATO is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes			Y
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes					Y
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes					Y

International Patents for DOVATO

When does loss-of-exclusivity occur for DOVATO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DOVATO around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	3551
Australia	2011209788
Australia	2014202404
Australia	2014202405
Australia	2014202406
Australia	2016204987

Supplementary Protection Certificates for DOVATO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	C300676	Netherlands		PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
1874117	CA 2014 00032	Denmark		PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
1874117	PA2014021	Lithuania		PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116
1874117	1490036-9	Sweden		PRODUCT NAME: DOLUTEGRAVIR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT ELLER SOLVAT DAERAV, INKLUSIVE DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892 20140116
1874117	C20140020 00130	Estonia		PRODUCT NAME: DOLUTEGRAVIIR;REG NO/DATE: K(2014)305 (LOPLIK) 21.01.2014
1874117	14C0041	France		PRODUCT NAME: DOLUTEGRAVIR ET SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,NOTAMMENT LE DOLUTEGRAVIR SODIQUE.; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121

DOVATO (dolutegravir/lamivudine) Market Dynamics and Financial Trajectory: Patent, Exclusivity, Competitive Landscape, and Revenue Exposure

Last updated: July 21, 2026

Executive summary: Dovato (dolutegravir/lamivudine, DTG/3TC) is an HIV-1 two-drug regimen that has converted well into US mainstream use and expanded into additional geographies through label-adjacent indications and guideline alignment. Financial trajectory is driven by (1) continued first-line penetration in treatment-naïve patients, (2) switch volume from dolutegravir-based three-drug regimens, and (3) competitive pressure from other dolutegravir-based combinations and integrase inhibitor plus NRTI backbones. The near-term earnings risk is concentrated in US and ex-US share dynamics rather than immediate generic displacement, because dolutegravir component protection and combination-specific patent estates slow Entry.

---

How fast is DOVATO growing in HIV two-drug therapy and what drives uptake?

Featured snippet answer: Dovato growth is primarily uptake in treatment-naïve first-line and switch populations within US and Western markets, supported by once-daily dosing, high barrier to resistance for dolutegravir-based therapy, and simplified regimen management versus three-drug ART.

What patient segments buy the most Dovato?

Dovato’s commercial momentum typically tracks three cohorts:

• Treatment-naïve patients eligible for 2-drug ART by label criteria and local guideline positioning.
• Virologically suppressed switch patients seeking regimen simplification from a stable three-drug regimen.
• Post-exposure and adherence-sensitive subgroups where once-daily fixed-dose simplification matters operationally (payer and provider workflows).

What market structure determines share?

Key determinants of Dovato demand:

• Formulary placement and payer management for INSTI/NRTI backbones.
• Guideline preference for dolutegravir-containing regimens where 2-drug ART is recommended.
• Hospital and clinic contracting patterns, especially for fixed-dose combinations.
• Inventory and specialty pharmacy distribution dynamics, where supply stability influences continuity of prescribing.

---

What patents protect DOVATO and how long does exclusivity last?

Featured snippet answer: Dovato’s generic risk is tempered by overlapping intellectual property on dolutegravir and on combination-specific formulation and use, with exclusivity and patent term variability across jurisdictions.

How does the patent estate typically break down for Dovato?

Dovato protection is usually layered across:

• Active ingredient protection: dolutegravir composition and manufacturing.
• Combination protection: fixed-dose DTG/3TC composition claims.
• Formulation and processing: solid-state, polymorph, stability, and manufacturing method claims for the fixed-dose product.
• Method-of-use protection: treatment regimens, dosing schedules, and patient selection criteria.

Key legal and regulatory linkages that affect launch timing

• Orange Book listings for the combination product (US) drive which patents a generic challenger must address.
• Paragraph IV timing hinges on patent expiration and listing strength.
• Settlement and licensing can move generic launch earlier or later than statutory minimum dates.

The rest of this section requires specific patent numbers, Orange Book listing identifiers, expiration dates, and any known Paragraph IV dockets to be accurate. Without those enumerated datapoints, a complete exclusivity timeline for Dovato cannot be produced without risking factual errors.

---

When does DOVATO lose exclusivity in the US and major markets?

Featured snippet answer: Dovato’s exclusivity loss is not a single date; it depends on (1) US patent expiration(s) tied to Orange Book listings, (2) potential pediatric or supplementary protection where applicable, and (3) country-level patent term and patent validity outcomes.

What drives “first possible generic” for DTG/3TC in the US?

• Expiration of the last Orange Book patent listed for the combination and the relevant dosage form (fixed-dose tablet).
• Court decisions in any patent litigation affecting listed claims.
• Exclusivity periods tied to regulatory marketing exclusivities that can pause generic approvals.
• Payer contracting cycles that allow a slower conversion from branded to generic even after regulatory approval.

Ex-US timing risks that move launch dates

• Different patent term adjustments and national phase timelines.
• Validity outcomes vary by jurisdiction.
• Local guideline inertia can delay uptake even when generics are available.

To produce a usable “loss of exclusivity” schedule with dates and jurisdictions, the patent list and regulatory exclusivities must be enumerated from authoritative records (Orange Book, national registries, and litigation dockets).

---

What generic entry risks exist for DOVATO and where are they concentrated?

Featured snippet answer: Generic entry risk is concentrated in markets with faster formulary switching and where patent estates (combination and formulation claims) are weakest or have already been narrowed by litigation outcomes.

How Paragraph IV challenges translate into commercial impact

A Paragraph IV filing typically creates:

• A regulatory approval stay tied to litigation timelines.
• A settlement probability that can define launch dates months to years ahead of the default statutory path.
• A payer renegotiation wave that reduces net price even before launch.

What factors reduce payer conversion even after approval?

• Contractual price differentials and supply continuity.
• Guideline-based prescribing habits favoring integrase-inhibitor regimens already on formulary.
• Specialty pharmacy switching friction for stable suppressed patients.

A precise “entry risk” ranking requires identification of challengers, docket numbers, and listed patents asserted, none of which can be stated accurately here without record-level citation.

---

Which companies compete with DOVATO in HIV two-drug regimens?

Featured snippet answer: Competition spans dolutegravir-based fixed-dose combinations and other 2-drug and simplified ART regimens, with major pressure from Gilead’s tenofovir-based combinations and ViiV’s INSTI/NRTI portfolio depending on guideline and formulary placement.

Competitive set (commercially relevant categories)

• Dolutegravir-containing backbones (DTG-based fixed-dose single-tablet regimens).
• Two-drug strategies using alternative backbones.
• Triple-drug INSTI regimens where payers favor single-entity contracting.

What determines whether payers prefer Dovato vs a triple?

• Incremental efficacy outcomes and resistance profiles under real-world adherence.
• Renal and bone safety profiles if payers push away from tenofovir disoproxil fumarate.
• Drug-drug interaction management and comorbidity burden.

---

How does DOVATO’s pricing and net revenue trajectory compare with other HIV branded therapies?

Featured snippet answer: Net revenue trajectory depends on the gap between wholesale acquisition cost (WAC) and realized net pricing, which moves with (1) formulary rebates, (2) competitive contracting, and (3) generic threat expectations.

What typically happens as competition increases?

• Gross-to-net dilution accelerates through rebates and contract price concessions.
• Switch-from-brand persists longer when patients are stable and regimens are optimized for tolerability and resistance risk.
• Volume elasticity improves once generics of alternative regimens enter, even if Dovato itself is still protected.

Comparable financial benchmarking requires disclosed revenue data, product net sales, payer mix, and segment reporting by the manufacturer, which is not provided in the prompt.

---

What is the Orange Book status of DOVATO and how many patents cover the product?

Featured snippet answer: Orange Book coverage is defined by the number of listed patents attached to Dovato’s FDA-approved fixed-dose tablet(s) and their specific claim scopes (composition, formulation, method-of-use).

Patent coverage structure you would expect to see

• Drug substance and/or drug product patents for dolutegravir and fixed-dose combination.
• Method-of-use claims for treatment regimens in eligible populations.
• Manufacturing/process claims that can block “same product” fabrication even if generics change non-critical aspects.

Without the Orange Book listing table (patent numbers, expiration dates, and claim types), the “how many patents” and “status” questions cannot be answered accurately.

---

What patent litigation affects DOVATO and how could outcomes change launch timing?

Featured snippet answer: Litigation outcomes affecting Orange Book-listed claims typically determine whether a generic can launch immediately on approval or remains barred until claims are invalidated or a settlement permits entry.

How litigation changes the commercial timetable

• Claim invalidation can remove the stay and permit earlier approval.
• Injunctions or adverse judgments delay launch and keep branded pricing power intact.
• Settlements often create a defined launch date and sometimes include “carve-outs” such as non-overlapping strengths.

Litigation docket-level facts and outcomes are necessary for a correct, actionable statement and are not available in the prompt.

---

What formulations and dosing strengths are protected for DOVATO tablets?

Featured snippet answer: Dovato is a fixed-dose oral tablet containing dolutegravir 50 mg and lamivudine 300 mg (DTG/3TC 50/300) under a single-tablet dosing regimen; formulation and manufacturing patents may protect specific solid-state forms, stability windows, and processes.

What formulation protection usually blocks

• Generic replication of the fixed-dose product through control of particle size distribution, polymorph selection, and excipient interactions.
• Manufacturing method constraints intended to improve stability and bioavailability consistency.

A definitive “what formulations are protected” requires a specific claim-by-claim mapping from listed patents and formulation patent disclosures.

---

How does DOVATO compare with Biktarvy, Triumeq, and other INSTI regimens for market positioning?

Featured snippet answer: Dovato targets simplification via a two-drug regimen, positioning against INSTI-based triple therapies that remain strong in guideline-driven prescribing and payer contracting.

Positioning variables for Dovato vs triple therapy

• Renal and safety profile tradeoffs depending on backbone selection.
• Resistance barrier considerations for integrase inhibitor retention.
• Patient eligibility criteria that determine whether clinicians can switch to 2-drug ART.

Market effect of regimen simplification

Two-drug regimens can win when:

• Clinicians aim to reduce NRTI burden or avoid certain agent classes.
• Payers prefer simplified formularies or fewer co-medications.
• Patient adherence improves with single-tablet schedules.

A true head-to-head commercial forecast requires net sales data, formulary coverage metrics, and realized pricing for Dovato and its closest alternatives.

---

What settlement agreements or licensing deals influence DOVATO’s competitive timeline?

Featured snippet answer: Settlement agreements and licenses typically define a timetable for generic entry, sometimes adding design-around or market-share protection.

Specific Dovato-related settlement/license terms require record-level data from court filings or company disclosures.

---

What is DOVATO’s FDA regulatory pathway status and label expansion impact?

Featured snippet answer: Dovato is an FDA-approved HIV-1 antiretroviral regimen for defined adult populations; label scope and ongoing inclusion in guideline recommendations can lift addressable demand.

How label scope affects revenue

• Expanded eligible populations increases addressable patient pool.
• Expanded switching indications convert additional suppressed patients.
• Refinements in contraindications or lab monitoring requirements can reduce prescribing friction.

A complete regulatory status section requires the FDA approval history, label indication list, and any supplements affecting market size.

---

Key Takeaways

• Dovato’s market dynamics are dominated by two-drug regimen adoption in treatment-naïve and switch populations and by formulary-driven net pricing mechanics.
• The core competitive risk comes from dolutegravir and INSTI-centered alternatives, with payer contracting influencing realized margins.
• Patent and exclusivity questions cannot be answered with the required specificity (dates, counts, claim types, and litigation effects) without enumerating the Orange Book listings and patent/litigation record tied to Dovato.

---

FAQs

1. What patient eligibility criteria most affect DOVATO prescribing in treatment-naïve HIV?
2. How do payer formulary restrictions typically influence Dovato net price and volume in the US?
3. What are the main technical barriers for generic fixed-dose DTG/lamivudine tablet manufacturing?
4. How do dolutegravir-based triple therapies affect Dovato switch-share and persistence?
5. What litigation and settlement mechanics most influence generic launch timing for HIV combination tablets?

---

References

1. APA style reference list is not provided because no primary source records (Orange Book listings, FDA label history, court dockets, or company financial filings) were included in the prompt.

DrugChatter Q&A for DOVATO

Dovato mechanism of action?
Dovato patent in argentina?
When is dovato loosing patent in germany and switzerland?
Is dovato approved in hungary?
Dovato intellectual property patent expiry date?